PGNYHIGH SIGNALFINANCIAL10-K

PGNY delivered extraordinary growth with revenue surging 311% to $1.3B and net income jumping 322% to $58.5M, while reducing share buybacks by 73% and outstanding shares declining from 85.4M to 81.9M.

This represents a transformational year for Progyny with revenue crossing the $1B threshold and profitability scaling dramatically alongside the revenue growth. The company appears to have achieved significant operational leverage while simultaneously returning substantial capital to shareholders through buybacks, though the reduced buyback activity in the current period may signal management's focus on reinvestment or cash preservation.

Comparing 2026-02-27 vs 2025-03-03View on EDGAR →
FINANCIAL ANALYSIS

PGNY demonstrated exceptional financial performance with revenue, gross profit, and net income all growing over 300%, indicating strong operational leverage and margin expansion. While the company significantly reduced share buybacks from $300M to $82M and saw cash decline 31% to $112M, the overall balance sheet remained healthy with 22% growth in total assets and stockholders' equity. The dramatic revenue and profitability growth, combined with increased capex investment and reduced share count, suggests a company successfully scaling its platform while efficiently deploying capital.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+322.1%
$13.9M$58.5M

Net income grew 322.1% — bottom-line growth signals improving overall business health.

Gross Profit
P&L
+318%
$72.8M$304.5M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Revenue
P&L
+311.3%
$313.3M$1.3B

Strong top-line growth of 311.3% — accelerating demand or successful expansion into new markets.

Operating Income
P&L
+296.1%
$21.5M$85.3M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Capital Expenditure
Cash Flow
+240.6%
$5.4M$18.4M

Capital expenditure jumped 240.6% — major investment cycle underway; assess returns on deployment.

Share Buybacks
Cash Flow
-72.8%
$300.3M$81.7M

Buyback activity reduced 72.8% — capital being redeployed elsewhere or cash conservation underway.

Cash & Equivalents
Balance Sheet
-30.9%
$162.3M$112.2M

Cash declined 30.9% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Assets
Balance Sheet
+22.3%
$607.1M$742.4M

Asset base grew 22.3% — expansion through organic growth, acquisitions, or capital deployment.

Total Liabilities
Balance Sheet
+22.3%
$185.0M$226.4M

Liabilities increased 22.3% — monitor debt-to-equity ratio and interest coverage.

Stockholders Equity
Balance Sheet
+22.3%
$422.1M$516.0M

Equity base grew 22.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.

LANGUAGE CHANGES
NEW — 2026-02-27
PRIOR — 2025-03-03
ADDED
As of January 31, 2026, the registrant had 81,902,232 shares of common stock, $0.0001 par value per share, outstanding.
We operate in a highly regulated industry and must comply with a significant number of new and evolving legal and regulatory requirements, as well as complex judicial mandates, which could have an adverse impact on our business.
Our use of artificial intelligence may subject us to new or heightened legal, regulatory, ethical, operational or other challenges.
We are part of the broader healthcare industry and subject to increasing scrutiny, business requirements and regulation within our business, including with respect to Progyny Rx s PBM operations, which may adversely affect our business, financial condition and results of operations.
BUSINESS Overview Progyny is a global leader in women s health and family building solutions.
+7 more — sign up free →
REMOVED
As of January 31, 2025, the registrant had 85,413,283 shares of common stock, $0.0001 par value per share, outstanding.
If we fail to maintain an efficient pharmacy distribution network or if there is a disruption to our network of specialty pharmacies or their supply chains, our business, financial condition and results of operations could suffer.
We operate in a highly regulated industry and must comply with a significant number of new and evolving legal and regulatory requirements, as well as complex judicial mandates.
Our mission is to empower healthier, supported journeys through transformative fertility, family building and women's health benefits.
Progyny is a leading benefits management company specializing in fertility, family building and women's health benefits solutions in the United States.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →